Moderna's Cancer Vaccine Worked -- and the Stock Plunged Anyway. Here's What Investors Are Missing.The Motley Fool • Thursday
Merck Ends Nemtabrutinib Development: What's Next for Its Pipeline?Zacks Investment Research • Wednesday
Moderna, Inc. (MRNA) Presents at Jefferies Global Healthcare Conference 2026 TranscriptSeeking Alpha • Wednesday
Moderna Targets Year-End Cancer Therapy Filing, Sees Multibillion-Dollar OpportunityMarketBeat • Wednesday
Axsome Therapeutics vs. Moderna: Which Biotech Innovator Stock Is a Better Buy for 2027?The Motley Fool • 11/14/26
Moderna Issues Cost Outlook Amid Revenue Uncertainty, Stock FallsZacks Investment Research • 11/13/26
MRNA Stock Up 3% Since Q3 Earnings Release: How to Play the Stock?Zacks Investment Research • 11/12/26
The world's most sophisticated drug companies are putting billions into vaccines — despite the political environmentMarket Watch • 11/12/26
Moderna's Q3 Numbers May Have Seemed Impressive, but They Aren't Enough to Make the Stock a BuyThe Motley Fool • 11/09/26
Moderna (MRNA) Stock Hits 52-Week Highs After Q3 Earnings: Buy, Hold, or Sell?Zacks Investment Research • 11/06/26
MRNA Q3 Earnings Beat on COVID Sales, Raises '26 Outlook, Stock RisesZacks Investment Research • 11/06/26
Moderna Hits Five-Year High On Sales Beat; But The Real Story Is Still Its Cancer VaccineInvestors Business Daily • 11/06/26